ints 9 1. Primary and Key Secondary Endpoints 10 2. Other Secondary Endpoints 11 F. Other Considerations 11 1. Safety Considerations 11 2. Pharmacokinetic/Pharmacodynamic Considerations 12 EFTA_R1_00015158 EFTA01734944 Contains Nonbinding Recommendations Draft — Not for Implementation Low Sexual Interest, Desire, and/or Arousa